Humabs BioMed Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 37

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

Humabs BioMed General Information

Description

Developer of human monoclonal antibodies created to treat a wide range of serious infections in the human body. The company's human monoclonal antibodies have passed natural selection by the human immune system in response to viral and bacterial diseases, in addition, it also developed anti-infective immunotherapies for the treatment of induce protective and therapeutic immune responses which solutions are non-existent or inadequate, enabling patients and pharmaceutical companies to get drugs for the treatment of rare diseases.

Contact Information

Website
www.humabs.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Via Mirasole 1
  • 6500 Bellinzona
  • Switzerland
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Biotechnology
Drug Discovery
Acquirer
Vir
Vertical(s)
Life Sciences
Corporate Office
  • Via Mirasole 1
  • 6500 Bellinzona
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Humabs BioMed Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Humabs BioMed‘s full profile, request access.

Request a free trial

Humabs BioMed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of human monoclonal antibodies created to treat a wide range of serious infections in the human body. The comp
Other Pharmaceuticals and Biotechnology
Bellinzona, Switzerland
37 As of 2021

Thousand Oaks, CA
 

Houston, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Humabs BioMed Competitors (74)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Amgen Formerly PE-Backed Thousand Oaks, CA
OncoResponse Venture Capital-Backed Houston, TX
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Kite Pharma Formerly VC-backed Santa Monica, CA
Light Chain Bioscience Private Equity-Backed Geneva, Switzerland
You’re viewing 5 of 74 competitors. Get the full list »

Humabs BioMed Patents

  • 227

    Total Documents Applications and Grants

  • Total Patents Families

  • 124

    Granted

  • 95

    Pending

  • Expiring in next 12 mo

Humabs BioMed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3218489-A1 Engineered polypeptides Pending 24-May-2021
AU-2022280767-A1 Engineered polypeptides Pending 24-May-2021
JP-2024521131-A Engineered polypeptides Pending 24-May-2021
EP-4347642-A2 Engineered polypeptides Pending 24-May-2021
EP-4291575-A1 Antibodies against respiratory syncytial virus, human metapneumovirus and pneumonia virus of mice and methods of using the same Pending 09-Feb-2021 C07K16/1027
To view Humabs BioMed’s complete patent history, request access »

Humabs BioMed Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Humabs BioMed FAQs

  • When was Humabs BioMed founded?

    Humabs BioMed was founded in 2004.

  • Where is Humabs BioMed headquartered?

    Humabs BioMed is headquartered in Bellinzona, Switzerland.

  • What is the size of Humabs BioMed?

    Humabs BioMed has 37 total employees.

  • What industry is Humabs BioMed in?

    Humabs BioMed’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Humabs BioMed a private or public company?

    Humabs BioMed is a Private company.

  • What is Humabs BioMed’s current revenue?

    The current revenue for Humabs BioMed is .

  • Who are Humabs BioMed’s competitors?

    Amgen, OncoResponse, CytomX Therapeutics, Kite Pharma, and Light Chain Bioscience are some of the 74 competitors of Humabs BioMed.

  • When was Humabs BioMed acquired?

    Humabs BioMed was acquired on 25-Sep-2017.

  • Who acquired Humabs BioMed?

    Humabs BioMed was acquired by Vir.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »